Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 19Terminated 6Unknown 5Recruiting 5Withdrawn 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 83Carcinoma, Non-Small-Cell Lung 79Breast Neoplasms 71Leukemia, Myeloid, Acute 39Colorectal Neoplasms 37Recurrence 36Prostatic Neoplasms 34Neoplasm Metastasis 30Multiple Myeloma 28Lymphoma 26Pancreatic Neoplasms 25Melanoma 25Lymphoma, Non-Hodgkin 24Lung Neoplasms 24Leukemia, Lymphocytic, Chronic, B-Cell 23Ovarian Neoplasms 22Lymphoma, Follicular 22Carcinoma, Hepatocellular 22Carcinoma, Renal Cell 21Stomach Neoplasms 19Squamous Cell Carcinoma of Head and Neck 19Lymphoma, Large B-Cell, Diffuse 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Myelodysplastic Syndromes 18Leukemia 18Head and Neck Neoplasms 18Urinary Bladder Neoplasms 17Hematologic Neoplasms 14Carcinoma 13Uterine Cervical Neoplasms 12

Interventions

cemiplimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × Advanced Malignancies × Clear all
NCT05245916 2023-09-05

IBI397 or Combination Therapies in Patients With Advanced Malignancies

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Withdrawn

Advanced Malignancies

NCT02520245 2016-11-07

Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study

Regeneron Pharmaceuticals

Phase 1 Withdrawn

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡